v3.26.1
Fair Value of Financial Instruments - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 6 Months Ended
Jun. 30, 2026
Apr. 06, 2026
Jan. 01, 2026
Jun. 30, 2026
Dec. 31, 2025
Apr. 01, 2025
Sep. 30, 2024
Fair Value, Option, Quantitative Disclosures [Line Items]              
Business combination contingent consideration liability $ 65,041     $ 65,041 $ 94,339    
Changes in fair value included in net income       31,755      
Maximum [Member]              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Changes in fair value included in net income       29,300      
SHINE              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Payment to dispose a business regarding related party transaction     $ 1,400        
Installment Note | Series E-1 Preferred Stock              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Estimated fair value   $ 70,000          
Carrying value 70,000 70,000          
Debt instrument, unamortized discount   2,500          
Gain on conversion   $ 2,500          
Installment Note | SHINE              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Promissory note receivable     $ 70,000        
Promissory note receivable maturity date     Jun. 14, 2028        
Seller Note | SHINE              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Unsecured promissory note receivable     $ 20,000        
Percentage of annual interest rate     8.00%        
Deferred Cash Purchase Price | Cash | SHINE              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Disposal group consideration     $ 25,000        
Deferred Cash Purchase Price | Cash on Earlier of January 1, 2029 | SHINE              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Disposal group consideration     20,000        
Deferred Cash Purchase Price | Cash After January 1, 2029 | SHINE              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Disposal group consideration     5,000        
SPECT              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Disposal group consideration 131,200   131,222 131,200      
SPECT | Cash              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Disposal group consideration [1]     32,141        
SPECT | Installment Note              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Disposal group consideration     67,200        
SPECT | Seller Note              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Disposal group consideration     14,500        
SPECT | Deferred Cash Purchase Price              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Disposal group consideration     12,300        
SPECT | Net Contingent Consideration Receivable              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Disposal group consideration     5,081        
SPECT | Fair Value of Contingent Consideration              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Disposal group consideration     6,500        
SPECT | Cash and capital stock              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Disposal group consideration     $ 30,000        
Life Molecular Imaging Inc              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Asset acquisition, additional milestone payments       400,000      
Milestone payments in cash       30,000      
Evergreen Theragnostics              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Business combination contingent consideration liability           $ 25,000  
Evergreen Theragnostics | Additional Remaining Payments              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Business combination contingent consideration liability $ 727,500     $ 727,500      
Radiopharm Theranostics Limited              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Shares owned (in shares) 537,958,513     537,958,513     149,625,180
Investment owned, fair value $ 7,000     $ 7,000 $ 9,000    
Share price (in dollars per share) $ 0.01     $ 0.01 $ 0.02    
Perspective Therapeutics, Inc              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Shares owned (in shares) 11,677,339     11,677,339      
Investment owned, fair value $ 39,800     $ 39,800 $ 32,100    
Share price (in dollars per share) $ 3.41     $ 3.41 $ 2.75    
Illuminated Holdings, Inc. | Installment Note | Series E-1 Preferred Stock              
Fair Value, Option, Quantitative Disclosures [Line Items]              
Shares owned (in shares)   2,545,454          
Conversion and cancellation amount   $ 70,000          
Note receivable Conversion Price   $ 27.5          
[1] This amount includes a net working capital settlement of $0.7 million, which was included in accounts receivable, net on the Company’s condensed consolidated balance sheet as of June 30, 2026 and subsequently received on July 1, 2026.